Freyherr Intnl Group - Statement re: Award of Good Distribution Practice
RNS Number : 0735X
Freyherr International Group PLC
17 December 2019
 

Freyherr International Group plc

 

Statement Re: Award of Good Distribution Practice Certificates

 

The Directors of Freyherr International Group plc ('Freyherr International' or 'the Company'), the medicinal cannabis group based in Slovenia, are pleased to announce that Freyherr Pharma, a company within Freyherr Group, has been issued with two good distribution practice ("GDP") certificates by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP).

The certificates, issued after inspection of the Company's facility at Koper, are for 'Compliance of a Wholesale Distributor' and for 'Compliance of a Distributor of Active Substances for use as starting materials in Medicinal Products for Human Use'. These certificates allow Freyherr to import active pharmaceutical ingredients ("APIs"), including cannabidiol ("CBD") from EU member states and distribute APIs within and outside the EU.

The award of this GDP certification for APIs confirms Freyherr commitment to the highest standards of compliance in every aspect of its warehousing and logistic activities. The GDP system for APIs ensures that the quality and integrity of APIs is maintained throughout the supply chain, including authorisation according to EU legislation; storage in controlled conditions at all times and the avoidance of contamination by or of other products.

Mr Frelih, the CEO of Freyherr, commented:

"Obtaining this new certification reinforces the solid basis we have created for dealing with pharmaceutical material and we continue to upgrade our facilities and look forward to extending the system to other cannabis materials and becoming a valued partner in pharmaceutical distribution."

The directors of the issuer accept responsibility for the contents of this announcement

For further information please contact:

 

FREYHERR INTERNATIONAL GROUP PLC

 

 

Tomaž Frelih

Freyherr International Group plc

No.1 London Bridge

London SE1 9BG

 

00 386 (41) 444 845

CITY & MERCHANT LIMITED

Corporate Advisor

David Papworth

Level 17 Dashwood House

69 Old Broad Street

London

EC2M 1QS

 

 

0207 101 7676

info@cityandmerchant.co.uk

HELFORD CAPITAL PARTNERS LLP

Investor Relations

Tony Burke

97 Jermyn Street

London

SW1Y 6JE

 

 

020 7839 5081

 

Note to Editors:

Freyherr International Group plc is the UK parent company of a group engaged in the production of medicinal cannabis and CBD products. The group is committed to research, development, cultivation, processing and production of Active Pharmaceutical Ingredients ("APIs"), final products and dosing packaging. Operations are centered in Slovenia and the Group principally operates within the EU.

Freyherr Pharma d.o.o. is the pharmaceutical arm of the Group and holds an EU GMP certificate. It operates from a certified production facility, manufactures CBD products for the Group and produces white label CBD products for customers in various EU countries. Its quality assurance department specializes in EU pharmaceutical quality systems, and particularly those relating to cannabis specifically. An important strength of Freyherr Pharma is also research and development department which has expertise in the cultivation, processing, formulation and legal and regulatory compliance of cannabis-based products. Freyherr Pharma has also invested in cannabis production facilities in other jurisdictions.

Patron d.o.o. is the dispenser production arm which has been operating since 2015. It develops, produces and markets products suitable for dosing concentrates and extracts. The company also offers analytical services for determination of the cannabinoid content (CBD, THC and 11 other cannabinoids) of dried plant material, extracts, concentrates or finished products.


This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NEXTRBBTMBIBMJL ]]>